Workflow
Cogent Biosciences(COGT) - 2023 Q1 - Quarterly Report
COGTCogent Biosciences(COGT)2023-05-09 00:00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38443 Cogent Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5308248 (State or other jurisdi ...